HLX3902: A Trispecific T‑Cell Engager Rewiring the Immune Desert in Prostate Cancer

/in , /by

HLX3902 is a STEAP1×CD3×CD28 trispecific T‑cell engager developed as a potential first‑in‑class immunotherapy for prostate cancer. Prostate tumors are largely “cold” from an immunological standpoint. The microenvironment is immunosuppressive, T cells are scarce inside the tumor mass, and those that do infiltrate often burn out quickly after activation. Classical CD3‑only bispecific TCEs can force T […]

Read more

JZY3032 and Domain‑ALTeration Chimeras: A New Class of Proximity‑Based Therapeutics

/in /by

Chemical‑induced proximity (CIP) strategies have expanded the therapeutic toolbox by modulating protein–protein interactions, but classical approaches such as PROTACs and molecular glues often force unnatural pairings or stabilize existing interfaces, leading to variable or unpredictable effects. Domain‑ALTeration Chimeras (DALTACs) take a different path: instead of degrading targets or reinforcing native contacts, they selectively miswire endogenous […]

Read more

TBI‑001: A TRIB2‑Targeted Strategy to Counter Lineage Plasticity and Treatment‑Emergent Neuroendocrine Prostate Cancer

/in /by

A new experimental drug called TBI‑001 targets a protein called TRIB2 in advanced prostate cancer that has become resistant to hormone therapy and starts acquiring neuroendocrine features. This is particularly relevant for treatment‑emergent neuroendocrine prostate cancer (t‑NEPC), a lethal subtype that arises after long‑term androgen‑receptor–targeted therapy, loses dependence on AR signaling, and adopts a neuroendocrine […]

Read more

A First‑in‑Class Dual AR‑V7/AR Molecular Glue Degrader for Metastatic Castration‑Resistant Prostate Cancer

/in /by

Most prostate cancer treatments today target the part of the AR protein that binds hormones, known as the ligand‑binding domain or LBD. At first these drugs like enzalutamide and abiraterone can shrink tumors or slow progression, but over time the cancer adapts and becomes resistant. This adaptation is a major reason why men with mCRPC […]

Read more

Soon to Be Phase 1 Trial: FX‑111, A Selective ARon Degrader with the Potential to Rethink Androgen Deprivation in Prostate Cancer

/in , , /by

A novel approach to targeting androgen receptor signaling in prostate cancer is emerging with FX‑111, an experimental degrader that selectively removes the hormone‑bound, transcriptionally active form of the receptor known as ARon. In metastatic castration‑resistant prostate cancer (mCRPC), the androgen receptor remains a central driver in the vast majority of cases, yet resistance to current […]

Read more

Darolutamide Linked to Better Real‑World Outcomes than Enzalutamide or Apalutamide in nmCRPC

/in , /by

A large real‑world study in nonmetastatic castration‑resistant prostate cancer (nmCRPC) called DEAR‑EXT, published on Nature, has added new detail to how the three androgen receptor inhibitors (darolutamide, enzalutamide, and apalutamide) behave outside of randomized trials, using data from over 1,300 men treated in US urology practices between 2019 and 2023. The analysis builds on an […]

Read more

AI CellVoyager Agent Turns Single‑Cell RNA‑seq Data into Continuous Hypothesis Generation

/in /by

CellVoyager shows that AI can move from “run what I tell you” to “decide what’s worth doing next” in data analysis for single‑cell RNA‑seq. It acts like a junior comp‑bio postdoc: it reads your background, sees which analyses you already did, plans additional steps, runs them, and proposes biological hypotheses such as new pathway associations […]

Read more

Ferroptosis-Nanoparticles Turn Prostate Tumors Hot: Docetaxel + Light Wakes Immunity

/in , /by

Cancer drugs like docetaxel work against prostate, lung, and other cancers, but they hit the whole body and often do not fully wake up the immune system. In this study, the research team built tiny nanoparticles (about 100–120 nm across) that carry docetaxel plus a light‑activated dye (IR808) and are made to open mainly inside […]

Read more